Coherus Oncology, Inc. (CHRS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CHRS currently has 154M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 33.42% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 154.2M shares outstanding |
150M | 0 |
| Mar 09, 2026 |
10-K filing | 149.9M shares outstanding |
150M | 0 |
| Nov 06, 2025 |
10-Q filing | 116.2M shares outstanding |
120M | 0 |
| Aug 07, 2025 |
10-Q filing | 116.1M shares outstanding |
120M | 0 |
| May 12, 2025 |
10-Q filing | 115.9M shares outstanding |
120M | 0 |
| Mar 17, 2025 |
10-K filing | 114.8M shares outstanding |
110M | 0 |
| Nov 06, 2024 |
10-Q filing | 115.2M shares outstanding |
120M | 0 |
| Aug 08, 2024 |
10-Q filing | 114.8M shares outstanding |
110M | 0 |
| May 09, 2024 |
10-Q filing | 112.7M shares outstanding |
110M | 0 |
| Mar 15, 2024 |
10-K filing | 112.2M shares outstanding |
110M | 0 |
| Nov 06, 2023 |
10-Q filing | 109.1M shares outstanding |
110M | 0 |
| Oct 06, 2023 |
8-K filing: Coherus BioSciences, Inc. will issue approximately 2,225,513 shares of its Common Stock to a contract manufacturing organization for a price of $3.675 per share, representing an aggregate value of approximately $8.2 million, in a private placement offering. ($8.2M proceeds) |
87M | 9.5M |
| Aug 02, 2023 |
10-Q filing | 87.3M shares outstanding |
87M | 9.5M |
| May 18, 2023 |
8-K filing: Coherus BioSciences, Inc. completed the sale and issuance of 13,529,411 shares of Common Stock at a price of $4.25 per share, receiving net proceeds of approximately $53.5 million. ($53.5M proceeds) |
79M | 17M |
| May 08, 2023 |
10-Q filing | 79.3M shares outstanding |
79M | 17M |
| Mar 06, 2023 |
10-K filing | 77.6M shares outstanding |
78M | 19M |
| Nov 08, 2022 |
10-Q filing | 77.7M shares outstanding |
78M | 19M |
| Nov 08, 2022 |
S-3 filing: Coherus BioSciences, Inc. is offering common stock, preferred stock, and debt securities up to $150,000,000 in the aggregate from time to time in one or more offerings through underwriters, dealers and agents, or directly to purchasers. |
78M | 19M |
| Aug 04, 2022 |
10-Q filing | 77.6M shares outstanding |
78M | 0 |
| May 05, 2022 |
10-Q filing | 77.3M shares outstanding |
77M | 0 |
| Feb 23, 2022 |
10-K filing | 75.4M shares outstanding |
75M | 0 |
| Nov 08, 2021 |
10-Q filing | 79.0M shares outstanding |
79M | 0 |
| Aug 05, 2021 |
10-Q filing | 75.6M shares outstanding |
76M | 0 |
| May 06, 2021 |
10-Q filing | 72.8M shares outstanding |
73M | 0 |
| Feb 25, 2021 |
10-K filing | 71.4M shares outstanding |
71M | 0 |
| Nov 05, 2020 |
10-Q filing | 71.6M shares outstanding |
72M | 0 |
| Aug 06, 2020 |
10-Q filing | 71.1M shares outstanding |
71M | 0 |
| May 07, 2020 |
10-Q filing | 70.7M shares outstanding |
71M | 0 |
| Apr 17, 2020 |
8-K filing: Coherus BioSciences, Inc. closed its offering of $200,000,000 aggregate principal amount of 1.500% Convertible Senior Subordinated Notes due 2026 and may issue up to 15,524,793 shares of common stock upon conversion of the notes. |
70M | 0 |
| Feb 27, 2020 |
10-K filing | 69.7M shares outstanding |
70M | 0 |